Hybridon, Inc. (HBY) Reports 2004 Financial Results
10/19/2005 5:13:07 PM
More...
|
Hybridon, Inc. (HBY) Presents New Preclinical Antitumor Data At American Association for Cancer Research Supporting Its IMOxine Development Program
10/19/2005 5:13:05 PM
More...
|
Hybridon, Inc.'s (HBY) Toll-Like Receptor 9 Agonist Enhances Antitumor Activity Of Cetuximab In Preclinical Studies
10/19/2005 5:12:55 PM
More...
|
Hybridon, Inc. (HYBN) To Present At Biotechnology Industry Organization (BIO) CEO And Investor Conference
10/19/2005 5:12:48 PM
More...
|
BioSpace Celebrates A Decade Of Genetown™
10/19/2005 5:12:28 PM
More...
|
Hybridon, Inc. (HYBN) Provides Updated Interim Results For The Phase 1 Trial Of IMOxine(TM)
10/19/2005 5:12:16 PM
More...
|
Hybridon, Inc. (HYBN) Announces Two Presentations At The American College Of Allergy, Asthma, & Immunology Annual Meeting
10/19/2005 5:12:13 PM
More...
|
Hybridon, Inc. (HBY) To Present At Two Upcoming Conferences
10/19/2005 5:12:02 PM
More...
|
Hybridon (HYBN) Initiates Phase 2 Trial Of Its Oncology Drug Candidate, IMOxine(TM)
10/19/2005 5:11:56 PM
More...
|
Hybridon (HYBN) To Present At Rodman & Renshaw Techvest 6th Annual Healthcare Conference
10/19/2005 5:11:55 PM
More...
|
|